Pulmonary arterial hypertension (PAH) is a rare complication in patients with connective tissue diseases (CTDs), and it is associated with high mortality rates, particularly in patients with systemic sclerosis (SSc). 1 Studies have shown that patients with CTD-associated PAH (CTD-APAH) experience poorer survival compared with patients with idiopathic PAH (IPAH). [2] [3] [4] In addition, despite similar baseline hemodynamics, patients with PAH associated with SSc (SSc-APAH) have the poorest survival rates when compared with other CTD-APAH subgroups, including patients with systemic lupus erythematosus, mixed CTD, and rheumatoid arthritis, in both incident and prevalent populations. 3, 5 Risk score calculators have been developed for patients with PAH as a whole, incorporating variables predictive of high mortality, including World Health Organization (WHO) group 1 subgroup, age, sex, New York Heart Association (NYHA) functional class (FC), vital signs, 6-min walk distance (6MWD), brain natriuretic peptide (BNP) level, presence of pericardial eff usion, diff usion capacity of the lung for carbon monoxide (D lco ), and baseline hemodynamic variables such as mean right atrial pressure (mRAP), pulmonary vascular resistance (PVR), and cardiac output. 6, 7 A study focusing on the CTD-APAH population found that higher mRAP, lower 6MWD, higher FC, and the presence of a pericardial eff usion were predictive of death. 8 In contrast, studies including patients with SSc-APAH alone have identifi ed male sex, lower D lco , older age, and FC IV status as independent predictors of death. 9, 10 No studies have evaluated a large cohort of patients with CTD-APAH to identify unique predictors of mortality in patients with SSc-APAH. We sought to use the large Registry to Evaluate Early and Long-Term PAH Management (REVEAL Registry) cohort of patients with CTD-APAH to identify unique predictors of mortality in the patients with SSc-APAH compared with patients with CTD other than SSc (non-SSc-CTD)-APAH that may account for the mortality diff erences between these groups.
Materials and Methods

REVEAL Registry
Th e REVEAL Registry is a longitudinal registry involving 54 pulmonary hypertension centers in the United States ( e-Appendix 1 ). Each participating center obtained institutional review board approval prior to patient enrollment. Th e design and objectives of the REVEAL Registry are described elsewhere. 11 All patients provided informed consent prior to enrollment, and "enrollment" was defi ned as the date consent was given. "Diagnosis" was defi ned as the date of diagnostic right-sided heart catheterization (RHC) occurring at or before the date of enrollment. Patients with new diagnoses were defi ned as those whose diagnostic RHC occurred within 90 days of enrollment. All consecutive patients who, in the opinion of the enrolling investigator, had a clinical diagnosis of PAH WHO group 1 12 and met the following inclusion criteria were eligible for enrollment: (1) 
Data Collection
Th e data in the REVEAL Registry was collected prospectively, but the analyses for this study were performed retrospectively. Data collection methods have been described previously. 3 Patients were enrolled from March 2006 through December 2009. Demographics, clinical characteristics, and outcomes were assessed at enrollment and quarterly thereaft er. Th e database of 3,515 patients was locked on February 4, 2013, for the current analyses. We developed an algorithm ( Fig 1 ) to exclude patients with exercise-induced PAH, in accordance with the Dana Point Classifi cation Criteria, 12 and those with pulmonary capillary wedge pressure . 15 mm Hg, who have been shown to diff er in many respects from those meeting the traditional hemodynamic definition of PAH, 13 and included only patients with CTD-APAH. We also excluded those with evidence of significant interstitial lung disease (ILD), defined as those with evidence of "severe" fibrosis on highresolution CT scan of the chest or "moderate" fibrosis if pul monary function testing revealed a total lung capacity of , 60% predicted. 14 We divided the patients with CTD-APAH into those with SSc-APAH (SSc group) and those with non-SSc-CTD-APAH (non-SSc group).
Statistical Analysis
Baseline characteristics at the time of enrollment were compared between the SSc and non-SSc groups, using the Student t or Wilcoxon test to compare continuous variables and the x 2 or Fisher exact test to compare categorical variables. Because BNP levels were highly skewed, the variables were log transformed for comparison as continuous variables. Cumulative probabilities of survival at 3 years were calculated using the Kaplan-Meier estimator for both the previously and newly diagnosed populations, and diff erences between the SSc and non-SSc groups were compared using the log-rank test. Follow-up time was calculated from the date of enrollment. Cox regression models identified significant predictors of mortality in the SSc and non-SSc Figure 1 - 
Results
Baseline Characteristics in Patients With CTD-APAH
Of 3,515 patients enrolled in the REVEAL Registry, 815 were identified as having CTD-APAH ( Fig 1 ) . Of these, 804 (500 SSc and 304 non-SSc) who did not have significant ILD were selected for these analyses. The majority of patients in the non-SSc group had systemic lupus erythematosus-APAH or mixed CTD-APAH ( Table 1 ) . Patients with SSc were older and had a shorter time between diagnostic RHC and enrollment into the database than did the patients with non-SSc-CTD-APAH ( Table 2 ) . Patients with SSc-APAH had more severe disease overall, with a higher NYHA FC, shorter 6MWD, higher Borg dyspnea index, lower D lco , and higher BNP level. Patients with SSc-APAH were also more likely to have renal insufficiency and pericardial effusions than patients with non-SSc-CTD-APAH. Although there was a strong trend toward higher mRAP in the SSc group, there were no significant differences in hemodynamics or PAH-specific therapies at the time of enrollment in the SSc vs non-SSc groups.
populations. All variables identifi ed previously as candidate predictors of mortality in the overall REVEAL Registry population were evaluated in univariate and multivariate models. Stepwise selection was used to determine the fi nal model, retaining only variables with P , .05. SAS, version 9.1 (SAS Institute Inc) statistical soft ware was used for all analyses. 
Poorer Survival in SSc-APAH Compared With Non-SSc-CTD-APAH
Th ree-year survival in the SSc group was worse than in the non-SSc group in both the previously and newly ( Fig 2 ) . Figure 3 shows the univariate analyses of previously identifi ed predictors of mortality from the overall REVEAL Registry cohort in the SSc and non-SSc groups. In multivariate analyses, the following variables remained predictive of mortality in both the SSc and non-SSc groups: NYHA FC III or IV status and BNP . 180 pg/mL ( 
Unique Predictors of Mortality in SSc-APAH
Discussion
Our study provides further evidence that patients with SSc-APAH experience higher mortality rates than do patients with other CTD-APAH in both incident and prevalent populations. Our results validate the usefulness of the risk score calculator in patients with CTD-APAH, including in patients with SSc-APAH. We identifi ed several baseline risk factors that were significantly associated with mortality in the SSc-APAH population in comparison with the non-SSc-CTD-APAH population, including being an elderly man, having a low SBP, having poor exercise capacity, and having severe hemodynamic indices including elevated mRAP and PVR. Identifying patients with SSc-APAH with high mortality risk based on the presence of these unique predictors of mortality will enable physicians to monitor these patients more closely and escalate therapy when indicated.
Th ree-year survival in the newly diagnosed SSc-APAH population was 51%, which is similar to survival rates found in other cohorts assessed in the modern treatment era. 1, 5, 9, 15, 16 Other studies have found better survival rates (75%-81%) in patients with SSc-APAH; these rates are similar to the survival rate of 77% that we and others observed in patients with non-SSc-CTD-APAH. 3, 5, 10, 17, 18 This survival discrepancy could be related to early detection algorithms that have been implemented in these SSc-APAH cohorts, with the goal to initiate PAHspecifi c therapy when the disease is less severe. Survival in patients with non-SSc-CTD-APAH appears to be more similar to those with IPAH than to those with SSc-APAH, despite similar baseline hemodynamics and PAH-specifi c therapies. 3 Whether initiating aggressive PAH treatment in patients with SSc-APAH with a particular high mortality risk may improve outcomes remains an important question to be answered.
Overall, predictors identifi ed in the multivariate model in SSc-APAH were very similar to the core predictors for PAH as a whole, including all subtypes. 6 Our results concur with those of other studies on patients with SSc-APAH in that male sex, older age, and FC III and IV status were signifi cant predictors of death. 5, 9, 10, 15 Our results confi rmed those of a single-center study that identifi ed high PVR as a strong predictor of mortality. 19 Unlike these other studies, we did not fi nd that low D lco or glomerular fi ltration rate were predictive of mortality in the SSc-APAH group in multivariate analyses, although they were signifi cant in univariate analyses. Lefèvre et al 15 eff usion, low 6MWD, high mean pulmonary arterial pressure, poor cardiac index, and elevated mRAP were poor prognostic factors. Although pericardial eff usion lost its signifi cance in our multivariate analysis of patients with SSc-APAH, poor exercise capacity and elevated mRAP remained significant predictors of death. Interestingly, 6MWD , 165 m was predictive of death only in the SSc group, whereas 6MWD Ն 440 m was protective only in the non-SSc-CTD-APAH group in multivariate analyses. A potential explanation for these discrepancies is that patients with SSc can suff er from the presence of contractures and tendon friction rubs that can signifi cantly limit mobility (particularly those with diff use skin disease) in addition to other factors that limit exercise capacity (such as anemia and joint or muscle infl ammation) in patients with other CTDs. 20, 21 However, including all variables in the multivariate model without stepwise selection, 6MWD , 165 m was a signifi cant predictor of death in the non-SSc group (HR 5 2.03; 95% CI, 1.01-4.12; P 5 .05), and 6MWD Ն 440 m showed a trend toward a protective eff ect in the SSc group (HR 5 0.62; 95% CI, 0.33-1.15; P 5 .13). In addition, when we evaluated the eff ect of 6MWD on mortality risk in the various cutaneous subgroups of SSc, an increase in distance of 100 m was signifi cantly protective in all three groups ( P , .001): diff use HR 5 0.53 (95% CI, 0.38-0.75); limited 0.59 (95% CI, 0.51-0.68); unclassifi ed 0.54 (95% CI, 0.40-0.71 ).
In our study, BNP . 180 pg/mL increased the risk of death in both the SSc and non-SSc-APAH groups by more than twofold, as has also been shown in patients with IPAH. 22 We and others have shown that patients with SSc-APAH have markedly elevated BNP and N-terminal-pro-BNP (NT-pro-BNP) levels compared with patients with IPAH and patients with non-SSc-CTD-APAH. 3, 23 Williams et al 24 found in a UK SSc-APAH cohort that for every order of magnitude increase in baseline NT-pro-BNP level there was a fourfold increased risk of death ( P 5 .002). In addition, several studies have found that NT-pro-BNP is useful in the screening and early detection of PAH in patients with SSc, and this biomarker has been integrated into novel screening algorithms. [25] [26] [27] To our knowledge, our study is the fi rst to show that BNP is an independent predictor of mortality in patients with CTD-APAH and SSc-APAH, in particular. Unfortunately NT-pro-BNP levels were not available in 89% of our CTD-APAH cohort, and, therefore, they could not be included in the regression models. To our knowledge, this is the fi rst study to identify low baseline SBP Յ 110 mm Hg as an independent predictor of death in patients with SSc-APAH. Other studies have shown that low SBP, both at peak exercise and upon admission to the hospital for right-sided heart failure, is an independent risk factor for death in PAH. 28, 29 A potential pathophysiologic explanation for this fi nding is that the presence of high right ventricular pressure results in a more pronounced eff ect of low SBP on coronary perfusion. Th us, low SBP can lead to greater right ventricular dysfunction caused by ischemia. In addition, low SBP may be a sign of low cardiac output, reduced stroke volume, and neurohormonal activation. 29 Unless complicated by renal disease, patients with SSc have relatively low baseline BP, 30 and the mean SBP was 119 Ϯ 19 mm Hg in the patients with SSc-APAH in our study. Given that BP can be monitored easily, identifi cation of low baseline SBP as a risk factor in SSc-APAH is an important fi nding.
We did not fi nd that mild to moderate ILD was predictive of death in patients with SSc-APAH. Although a signifi cant predictor in the non-SSc-APAH group in univariate analysis, it was no longer signifi cant in multivariate analysis. We attempted to exclude patients with substantial ILD as defi ned previously but did not have precise measurements regarding the degree of fi brosis on imaging.
Our study does have some limitations. The SSc-APAH and non-SSc-CTD-APAH cohorts are smaller than the overall cohort. Thus, differences in significant multivariable predictors may be caused by loss of power as opposed to true differences in predictors for different subtypes. In addition, the model does not include therapies. Th e majority of REVEAL Registry patients, particularly patients who had previous diagnoses, were receiving phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclins, or a combination. Therefore, the model does not provide insights into prognosis for untreated patients. Although 86% of the patients with CTD-APAH were enrolled at sites that routinely involve a rheumatologist in the diagnosis and care of these patients, misclassification of some patients may have occurred. Finally, the analysis only assessed variables available in the REVEAL Registry database. There may be additional factors particular to patients with CTD-APAH, such as autoantibody status, that could impact the results.
Conclusions
In conclusion, patients with SSc-APAH have higher mortality rates than patients with non-SSc-CTD-APAH. Our results validate the usefulness of the PAH risk score in patients with SSc-APAH. We have identifi ed unique predictors of mortality in patients with SSc-APAH, including being an older man, having a low baseline SBP, having poor exercise capacity, and having an elevated mRAP and PVR; these can be used to identify high-risk patients who may benefi t from closer monitoring and more aggressive treatment.
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